|
Official Record of Patients Diagnosed with Lymphangioleiomyomatosis (LAM) Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Official Record of Patients Diagnosed with Lymphangioleiomyomatosis (LAM) conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Official Record of Patients Diagnosed with Lymphangioleiomyomatosis (LAM) Clinical research trials and Official Record of Patients Diagnosed with Lymphangioleiomyomatosis (LAM) medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Official Record of Patients Diagnosed with Lymphangioleiomyomatosis (LAM). Official Record of Patients Diagnosed with Lymphangioleiomyomatosis (LAM) Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Official Record of Patients Diagnosed with Lymphangioleiomyomatosis (LAM) clinical trial. Subjects typically recieve the finest healthcare available for their Official Record of Patients Diagnosed with Lymphangioleiomyomatosis (LAM) condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "O" Clinical Trials Conditions > Official Record of Patients Diagnosed with Lymphangioleiomyomatosis (LAM)  Official Record of Patients Diagnosed with Lymphangioleiomyomatosis (LAM)
Official Record of Patients Diagnosed with Lymphangioleiomyomatosis (LAM)
For Condition: Leiomyomatosis
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: Pulmonary lymphoangioleiomyomatosis (LAM) is a rare destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor. In order to better study this disease, the National Heart, Lung, and Blood Institute (NHLBI) has developed a registry to keep an official record of patients diagnosed with LAM. This research project will collect data from 6 health care centers as well as outside physicians. Researchers hope to provide valuable information about the rate of lung destruction and quality of life in patients with LAM. Patients participating in this study will be followed for 5 years. Tissue collected from these patients may contribute to the development of future studies on the disease processes of LAM.
Details: LAM is a rare disease that predominantly affects women of child-bearing age. To study in more detail this rare disease, this multi-center project will establish a registry of persons with LAM. By combining data from 6 centers and outside physicians, this study may yield valuable information regarding the rate of decline in pulmonary function and quality of life in individuals with LAM. These patients will be followed over a five-year period. Tissue collected from study participants may facilitate future studies into the molecular basis of LAM.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Informed consent must be obtained from the patient. Patients must be female. Patients must be age 18 or older. Patients with prevalent and incident cases are eligible. Patients with the presence or absence of underlying diagnosis or evidence of Tuberous Sclerosis Complex (TSC) are eligible. Patients must have a diagnosis of LAM confirmed by any of the following criteria: Lung biopsy (transbronchial, surgical, transthoracic) judged to be diagnostic by the Tissue Core pathologists; OR Biopsy of lymph node or other mass judged to be diagnostic by the Tissue Core pathologists; OR High resolution CT scan of the chest which is judged to be diagnostic of LAM with a high degree of certainty by all three of the expert radiologists making up the Imaging Core. Patients may be enrolled in other protocols.
Total Enrollment: 400
Location and Contact Information:
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 990020; 99-H-0020
Study Start Date: December 8, 1998
Record last reviewed: April 22, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001869
Other Leiomyomatosis Studies:
1. Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
2. Official Record of Patients Diagnosed with Lymphangioleiomyomatosis (LAM)
3. Study of the Disease Process of Lymphangioleiomyomatosis
Related Studies:
Other Leiomyomatosis Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Official Record of Patients Diagnosed with Lymphangioleiomyomatosis (LAM)
|
|
|
|
|
|
|
|
